Preclinical studies showed an antitumoral effect in HER-2-overexpressing breast cancer cells and greater efficacy when compared with both trastuzumab and T-DM1, with an antitumoral effect in T-DM1-resistant cancer cells [107]. Here, ERBB2 is linked to cancer.